Cardiovascular Drugs Market by Drug Type, Disease Indication, Route of Administration, Mode of Purchase, End-Users

Description

List of Tables

The Global Cardiovascular Drugs Market is forecasted to grow significantly, with a projected USD 82.65 billion in 2023 at a CAGR of 9.13% and expected to reach a staggering USD 152.61 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Cardiovascular Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Cardiovascular Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Drug Type, market is studied across Angiotensin Inhibitors, Anticoagulants, Antihyperlipidemic, Antihypertensive, and Antiplatelet Drugs. The Anticoagulants commanded largest market share of 32.12% in 2022, followed by Antihypertensive.

Based on Disease Indication, market is studied across Arrhythmia, Coronary Artery Disease, Hyperlipidaemia, and Hypertension. The Coronary Artery Disease commanded largest market share of 34.23% in 2022, followed by Hyperlipidaemia.

Based on Route of Administration, market is studied across Intravenous, Oral, and Subcutaneous. The Oral commanded largest market share of 57.23% in 2022, followed by Intravenous.

Based on Mode of Purchase, market is studied across Over-The-Counter Drugs and Prescription-Based Drugs. The Prescription-Based Drugs commanded largest market share of 82.12% in 2022, followed by Over-The-Counter Drugs.

Based on End-Users, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. The Retail Pharmacies commanded largest market share of 67.32% in 2022, followed by Hospital Pharmacies.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded largest market share of 37.00% in 2022, followed by Americas.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Cardiovascular Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Cardiovascular Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cardiovascular Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cardiovascular Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Cardiovascular Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Cardiovascular Drugs Market?

6. What is the market share of the leading vendors in the Global Cardiovascular Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Cardiovascular Drugs Market?

Product Code: MRR-434CCDA0519A

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Cardiovascular Drugs Market, by Drug Type, 2022 vs 2030
4.3. Cardiovascular Drugs Market, by Disease Indication, 2022 vs 2030
4.4. Cardiovascular Drugs Market, by Route of Administration, 2022 vs 2030
4.5. Cardiovascular Drugs Market, by Mode of Purchase, 2022 vs 2030
4.6. Cardiovascular Drugs Market, by End-Users, 2022 vs 2030
4.7. Cardiovascular Drugs Market, by Region, 2022 vs 2030

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising Prevalence of Cardiovascular Disorders
  - 5.1.1.2. Increasing R&D Investments for Drug Development
  - 5.1.1.3. Government Initiatives for Prevention & Control of Cardiovascular Diseases
- 5.1.2. Restraints
  - 5.1.2.1. Product Recalls and High Cost of Cardiovascular Drugs
- 5.1.3. Opportunities
  - 5.1.3.1. Favorable Reimbursement Policies and Programs for Cardiovascular Drugs
  - 5.1.3.2. Introduction of Novel Drugs for Treatment of Cardiovascular Diseases
- 5.1.4. Challenges
  - 5.1.4.1. Complexities in Efficient and Safe Drug Development
5.2. Market Trends
5.3. Cumulative Impact of COVID-19
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework
5.9. Client Customization

6. Cardiovascular Drugs Market, by Drug Type

6.1. Introduction
6.2. Angiotensin Inhibitors
6.3. Anticoagulants
6.4. Antihyperlipidemic
6.5. Antihypertensive
6.6. Antiplatelet Drugs

7. Cardiovascular Drugs Market, by Disease Indication

7.1. Introduction
7.2. Arrhythmia
7.3. Coronary Artery Disease
7.4. Hyperlipidaemia
7.5. Hypertension

8. Cardiovascular Drugs Market, by Route of Administration

8.1. Introduction
8.2. Intravenous
8.3. Oral
8.4. Subcutaneous

9. Cardiovascular Drugs Market, by Mode of Purchase

9.1. Introduction
9.2. Over-The-Counter Drugs
9.3. Prescription-Based Drugs

10. Cardiovascular Drugs Market, by End-Users

10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies

11. Americas Cardiovascular Drugs Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Cardiovascular Drugs Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Cardiovascular Drugs Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player

15. List of Company Mentioned

16. Appendix

16.1. Discussion Guide
16.2. License & Pricing